

ASX MEDIA RELEASE

3 May 2024

Clarity to present at three world leading conferences

HIGHLIGHTS

- Eight abstracts have been accepted by the American Urological Association (AUA), American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meetings, showcasing the latest data from Clarity’s oncology portfolio.
- Abstracts of Clarity’s diagnostic clinical trials COBRA and CLARIFY were accepted for oral presentation at SNMMI and AUA Annual Meetings, respectively.
- Additional abstracts were accepted for the SECuRE, COBRA and CLARIFY trials at ASCO, and for the SECuRE, COMBAT and SABRE trials at SNMMI.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that new data will be presented at the upcoming AUA, ASCO and SNMMI 2024 Annual Meetings, covering clinical results and trials in progress. The data showcases the extensive scope of Clarity’s Targeted Copper Theranostic (TCT) platform in developing multiple products for imaging and treating cancer patients, with focus on prostate cancer.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The AUA, ASCO and SNMMI Annual Meetings are among the most prestigious conferences in urology, oncology and nuclear medicine, respectively. We are delighted that our data has been accepted for presentation at these world leading conferences. The abstracts accepted for presentations, including two oral presentations, highlight the exciting opportunities for our next-generation TCT radiopharmaceuticals as we continue to generate incredible data on what we strongly believe to be best in class assets for the treatment and diagnosis of cancer.

“We are looking forward to sharing this data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate exciting results to date while expanding the platform into multiple indications. We are also looking forward to further developing our existing as well as novel TCT products as we get closer to our ultimate goal of improving treatment outcomes for children and adults with cancer.”

Data to be presented at 2024 AUA, ASCO and SNMMI Annual Meetings

Product	Abstract Title	Conference
⁶⁴ Cu-SAR-bisPSMA	CLARIFY: Positron Emission Tomography using ⁶⁴ Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, a phase 3 diagnostic study	AUA – Oral presentation <i>Session Date</i> Sunday, May 5 th <i>Session Time</i> 1:00-3:00 PM CT <i>Session Title</i> Clinical Trials in Progress—Cancer

⁶⁴ Cu-SAR-bisPSMA	COBRA: Assessment of safety and efficacy of ⁶⁴ Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy	<p>ASCO – Poster presentation</p> <p><i>Session Date</i> Sunday, June 2nd</p> <p><i>Session Time</i> 9:00 AM – 12:00 PM CT</p> <p><i>Session Title/Track</i> Genitourinary Cancer—Prostate, Testicular, and Penile</p> <p><i>Sub Track</i> Prostate Cancer—Local-Regional Disease</p> <p>Abstract # 5100 Poster Bd # 506</p>
⁶⁴ Cu-SAR-bisPSMA	CLARIFY: Positron emission tomography using ⁶⁴ Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study)	<p>ASCO – Poster presentation</p> <p><i>Session Date</i> Sunday, June 2nd</p> <p><i>Session Time</i> 9:00 AM – 12:00 PM CT</p> <p><i>Session Title/Track</i> Genitourinary Cancer—Prostate, Testicular, and Penile</p> <p><i>Sub Track</i> Prostate Cancer—Local-Regional Disease</p> <p>Abstract # TPS5129 Poster Bd # 524a</p>
⁶⁷ Cu-SAR-bisPSMA	SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of ⁶⁷ Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer	<p>ASCO – Poster presentation</p> <p><i>Session Date</i> Sunday, June 2nd</p> <p><i>Session Time</i> 9:00 AM – 12:00 PM CT</p> <p><i>Session Title/Track</i> Genitourinary Cancer—Prostate, Testicular, and Penile</p> <p><i>Sub Track</i> Prostate Cancer– Advanced/Castrate-Resistant</p> <p>Abstract # TPS5116 Poster Bd # 517b</p>
⁶⁴ Cu-SAR-bisPSMA	COBRA: Assessment of safety and efficacy of ⁶⁴ Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy	<p>SNMMI – Oral presentation</p> <p><i>Session Date</i> Tuesday, June 11th</p> <p><i>Session Time</i> 8:00 AM - 9:15 AM ET</p> <p><i>Session Title</i> Prostate Cancer - Radiomics/Data Analysis</p>
⁶⁷ Cu-SAR-bisPSMA	SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of ⁶⁷ Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer	<p>SNMMI – Poster presentation</p>

⁶⁷ Cu-SAR-BBN	COMBAT: A study of ⁶⁴ Cu-SAR-BBN and ⁶⁷ Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate resistant prostate cancer ineligible for therapy with ¹⁷⁷ Lu-PSMA-617	SNMMI – Poster presentation
⁶⁴ Cu-SAR-BBN	SABRE: Assessment of safety and efficacy of ⁶⁴ Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patients	SNMMI – Poster presentation

Posters and presentations containing study results will be available on Clarity’s official website after their presentation at the 2024 AUA, ASCO and SNMMI Annual Meetings:

[claritypharmaceuticals.com/pipeline/scientific_presentations](https://www.claritypharmaceuticals.com/pipeline/scientific_presentations)

Abstracts for the 2024 ASCO Annual Meeting will be released on the 23rd of May at 5 PM ET and will be available at the conference website: conferences.asco.org/am/abstracts

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR technology platform for the treatment of children and adults with cancer.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor
Executive Chairperson
ataylor@claritypharm.com

Catherine Strong
Investor/Media Relations
c.strong@morrrowsodali.com
 +61 406 759 268

This announcement has been authorised for release by the Executive Chairperson.